Original ResearchVismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial☆
Under a Creative Commons license
open access
Keywords
Vismodegib
Hedgehog pathway inhibitor
Basal cell carcinoma
Gorlin syndrome
STEVIE
Cited by (0)
- ☆
Prior presentations: The primary analysis from the STEVIE study was presented in part at the 2016 Annual Meeting of the American Society of Clinical Oncology, June 3–7, 2016, Chicago, IL, USA.
- 1
Current affiliation: Global Clinical Research Oncology, Bristol-Myers Squibb Pharmaceuticals Ltd, BMS House, Sanderson Rd., Uxbridge, Middlesex, UB8 1DH, UK.
© 2017 The Authors. Published by Elsevier Ltd.